- Advertisement -spot_img
Friday, July 19, 2024

Top 10 CRO Solution Providers 2022

According to some of the recent research, the pharmaceutical contract research organization (CRO) industry today was valued $40 billion by 2020 and is expected to double soon. However, the report also states that only 50% of clinical development is currently outsourced. This is expected to rise amid rising cost and complexity of therapeutic development in an increasingly burdensome reimbursement and stringent regulatory environment.

The CRO industry is highly fragmented with hundreds of small to mid-sized companies amid low industry barriers to entry. However there are a small number of large, full-service, global CROs offering broad therapeutic and development expertise with substantial scale, capabilities, IT systems infrastructure and data analytics capability. Over the past few years, there has been some consolidation in the CRO industry, leaving only a handful of larger CROs with the global scale and infrastructure, therapeutic and development expertise to support and fulfill the demanding drug development programs of biopharmaceutical and medical device companies. Moreover, the technological adoption including AI and machine learning tools are rapidly increasing in the CRO space.

At this juncture, as companies around the globe are struggling to find the right solutions provider, we’ve developed this special edition on CRO Solution Providers 2022. The companies listed below are shortlisted by our team of researchers, CEO, CTOs and healthcare solutions experts. We present to you “Top 10 CRO Solution Providers 2022.”

Altasciences

Management:

Chris Perkin

Designation:

CEO

Headquarters:

Laval, Quebec

Website:

altasciences.com

An integrated drug development solution company, offering pharmaceutical and biotechnology companies a proven, flexible approach that removes the need for multiple service providers during the early stages of drug development. Whether for one study or an end-to-end program, we help you reach critical decision-making milestones sooner by improving speed and ease from lead candidate selection to clinical proof of concept, and beyond.

Calian Group

Management:

Kevin Ford

Designation:

CEO

Headquarters:

On, Canada

Website:

calian.com

Calian helps people communicate, innovate, learn, stay safe and lead healthy lives with confidence. Every day, the company’s employees live values of customer-centricity, integrity, innovation and teamwork to engineer reliable solutions that solve complex problems. A stable and growing company for 40 years, Calian is headquartered in Ottawa with offices and projects spanning North American and international markets.

Clinilabs

Management:

Gary Zammit, PhD

Designation:

President & CEO

Headquarters:

Eatontown, NJ

Website:

clinilabs.com

Clinilabs Drug Development Corporation is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development. With deep expertise in CNS, we are committed to the development of medicines that treat a range of psychiatric, neurological and substance use disorders, as well as rare and ultra-rare CNS diseases.

Frontagelab

Management:

Song Li

Designation:

CEO

Headquarters:

Exton, PA

Website:

frontagelab.com

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals.

ICON plc

Management:

Dr. Steve Cutler

Designation:

CEO

Headquarters:

Dublin, Ireland

Website:

iconplc.com

ICON is a global provider of consulting, and outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company focus its innovation on the factors that are critical to clients – reducing time to market, reducing cost and increasing quality – and a global team of experts has extensive experience in a broad range of therapeutic areas.

IQVIA

Management:

Ari Bousbib

Designation:

Chariman & CEO

Headquarters:

Durham, NC

Website:

iqvua.com

IQVIA is a global leader in preserving the privacy of individual patients. The company employs a variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing data on a large scale to assist healthcare stakeholders in identifying disease patterns and correlating them to the precise treatment path and therapy required for better outcomes.

Mediconomics

Management:

Dr. Uwe Albrecht

Designation:

Founder & CEO

Headquarters:

Hannover, Germany

Website:

mediconomics.com

Mediconomics is a successful CRO and consultant for research and development projects of both Medicinal Products and Medical Devices. Headquartered in Hannover, Germany and with subsidiaries in Denmark, Switzerland, the UK and US, Mediconomics operates within an international network. It goes without saying that all activities are compliant with the relevant guidelines in the consistently-changing regulatory environment.

Medpace

Management:

August J. Troendle

Designation:

Chairman & CEO

Headquarters:

Cincinnati, OH

Website:

medpace.com

Medpace is a full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services to biotechnology, pharmaceutical, and medical device companies. Medpace is putting medical, operational, and regulatory expertise into practice, utilizing proven KOL and site partnerships to help researchers succeed. Medpace is distinctive in that it approaches clinical research from a scientific standpoint.

Parexel

Management:

Jamie Macdonald

Designation:

CEO

Headquarters:

Newton, MA

Website:

parexel.com

As one of the world's leading global clinical research organizations (CRO), Parexel provide the clinical development capabilities and integrated consulting expertise it takes to streamline development every step of the way — faster and more cost-effectively. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, the company's therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in its DNA.

Synteract

Management:

Steve Powell

Designation:

CEO

Headquarters:

Carlsbad, CA

Website:

synteract.com

Synteract, a Syneos Health company, is a leading full service CRO focused on the emerging biopharma segment. The Company’s multidisciplinary teams support biotech and pharmaceutical companies across all phases of drug development, providing deep expertise in oncology, dermatology, general medicine, infectious disease and vaccines, neuroscience, pediatrics, and rare and orphan diseases.

Translate »